ArticleCancer gene therapy2022

MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.

Li-Ying Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.